SPRIM joins in support of International NASH Day
Today is International NASH Day!
SPRIM and our portfolio company, Fibronostics, are proud to join the Global Liver Institute (GLI) in raising awareness of this important health issue.
Non-alcoholic steatohepatitis, or NASH, has been called an epidemic, a ticking time bomb, and a silent tsunami. It is the progressive form of non-alcoholic fatty liver disease (NAFLD) and affects more than 115 million people worldwide. An estimated 357 million people will be affected by 2030.
Because NASH symptoms are not overt, NASH is often underdiagnosed and underreported. NAFLD and NASH are major risk factors for other health conditions: more than 70% of patients are obese, up to 75% have type 2 diabetes, and anywhere from 20-80% have hyperlipidemia. Unchecked, NASH may lead to cirrhosis, liver cancer, and liver transplant.
Despite its prevalence and serious health consequences, NASH is relatively unknown. In a recent survey, only 6% of at-risk individuals had ever heard of NASH.
Against this backdrop, the first International NASH Day (IND) was launched on June 12, 2018, with the goal of raising awareness about NASH and the actions people can take to prevent the disease. Now under the Global Liver Institute’s leadership, International NASH Day is set to build off last year’s successes.
“We urge everyone to spread the word about NASH and its effects,” Donna Cryer, GLI’s President and Founder said. “Our goal is to shine light on this silent epidemic.”
Fibronostics, a healthcare technology company that provides algorithm-based solutions for liver disease detection, is also proud to join in support of the NASH day initiative.
The group recently announced its partnership with Ayala Healthcare Holdings, Inc. (AC Health), whose investment in the company will ultimately lead to the introduction of two Fibronostics products, LiverFAST and HealthFACTR, into its FamilyDOC clinics in the Philippines.
For more information, visit www.fibronostics.com
For more information on NASH Day, visit globalliver.org/IND.